Suprapolix

What Suprapolix does

SupraPolix BV is a privately-held materials science company headquartered in Eindhoven, the Netherlands, that develops and licenses supramolecular polymer technology based on its proprietary SupraB™ quadruple hydrogen bonding platform (derived from UPy/UreidoPyrimidone chemistry pioneered by Bert Meijer and Rint Sijbesma at Eindhoven University of Technology). The SupraB™ platform is offered as a technology platform and additive that can be incorporated into a wide range of polymer backbones, enabling self-healing behaviour, tunable rheology, lower-temperature or higher-speed processing, reversible bonding, and thermo-reversible hydrogels without the need for catalysts or toxic additives. Application areas span adhesives, specialty coatings, biomedical materials (including bioresorbable implants, hydrogels, and tissue engineering scaffolds), cosmetics, and broader plastics/polymers markets.

The company operates a B2B model centered on technology licensing of its IP portfolio (including optional supply of SupraB™ ingredients or polymers) and paid feasibility studies that serve as the entry point into longer-term R&D collaboration and licensing relationships. Direct industrial partners and academic collaborators include Eindhoven University of Technology, Xeltis, Coloplast, UPyTher, University Hospital Zürich, University Hospital Leuven, and University Hospital Antwerp, among others, with co-funding historically provided by DSM Venturing, TU/e Holding, and a syndicate of private investors. SupraPolix's growth has been supported by EU and regional grant funding (notably the EUR 2.8 million INJECTOGELS budget) and participation in multi-partner consortia such as ImaValve and an international bioabsorbable implants program.

The firm is led by CEO Tonny Bosman and CFO David Driessen, with co-inventor Bert Meijer chairing the non-executive board. Headcount is small (1-10), revenue is not publicly disclosed, and pricing for licenses and feasibility work is not published; commercial traction is inferred from partnerships and academic visibility rather than disclosed licensing income.

Name

Suprapolix

Legal name

SupraPolix BV

Website

https://suprapolix.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

SupraPolix BV is a privately-held Dutch materials company that develops and licenses its proprietary SupraB™ quadruple hydrogen bonding polymer platform, supplying self-healing, coatings, and biomedical materials to industrial partners via feasibility studies and IP licensing agreements.

Ownership category

akta.pro rank

Headquarters

HQ city

Eindhoven

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: License agreements that regulate access to SupraPolix's extensive IP portfolio, including supply of SupraB ingredients or polymers for commercial applications.
2. Feasibility Studies: Initial access to SupraB technology through feasibility studies dedicated to specific polymeric materials and application areas, creating opportunities for further collaboration.
3. R&D Collaboration Services: Product-applications containing SupraPolix proprietary materials are developed in collaboration with industrial clients, providing direct access to proprietary supramolecular technology and implementation know-how.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

SupraPolix develops and supplies its proprietary SupraB™ quadruple hydrogen bonding technology as an additive ingredient and as finished SupraMolecular Polymer materials for industrial clients. The technology enables self-healing behavior, tunable rheological properties, and the separation of polymer processability from material performance in plastics, adhesives, specialty coatings, biomedical implants, hydrogels, and cosmetics applications. The company monetizes its IP portfolio through licensing agreements and custom feasibility studies with industrial partners.

Product overview

SupraPolix is a materials science company offering a technology platform centered on its proprietary SupraB™ quadruple hydrogen bonding technology. The core product SupraB™ serves as an additive that can be incorporated into existing polymers to enable self-healing behavior, improved processing at lower temperatures, and tunable material performance. The SupraMolecular Polymers product line represents finished materials developed using this technology, spanning applications in adhesives, specialty coatings, biomedical materials (including hydrogels), and cosmetics. SupraPolix operates through feasibility studies and license agreements, offering initial access to the SupraB™ technology before commercial application.

Differentiator

Problem solved

Functional benefit

Brands

• SupraB™: Proprietary quadruple hydrogen bonding technology used to create supramolecular polymers with self-healing properties, tunable material performance, and unique processing conditions. Applied in adhesives, coatings, hydrogels, biomedical materials, and cosmetics.

Products and services

• SupraB™ Proprietary quadruple hydrogen bonding technology platform supplied as an additive ingredient. When incorporated into existing polymer systems, SupraB™ enables self-healing behavior, reversible bonding, tunable material performance, and improved processing at lower temperatures or higher speeds. Used by industrial clients in adhesives, specialty coatings, biomedical materials, and cosmetics.
• SupraMolecular Polymers Finished polymeric materials utilizing SupraB™ supramolecular interactions to increase virtual molecular weight, separating processability from material demands. Applications include adhesives, specialty coatings, biomedical materials, and cosmetics. Supplied to industrial clients for evaluation within feasibility studies and under licensing agreements.
• Feasibility Studies Dedicated feasibility studies offering industrial clients initial access to SupraB™ technology for specific polymeric materials and application areas, assessing technological possibilities and laying the groundwork for deeper collaboration or licensing relationships.
• R&D Collaboration Services Collaborative development of product-applications containing SupraPolix proprietary materials, providing industrial partners with direct access to SupraB™ supramolecular technology and implementation know-how within multi-partner consortia.
• SupraB™ Technology Licensing License agreements governing industrial partners' access to SupraPolix's IP portfolio, including rights to use SupraB™ linking strategies in industrial polymers and supply of SupraB ingredients or polymers for commercial application development.

Quantifiable outcome

• Self-healing without consuming material - the healing cycle can be repeated indefinitely
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• UPyThercoreStrategic or Co-development PartnerEindhoven-based partner in INJECTOGELS project funded by European Commission and Province of North Brabant with EUR 2.8M budget, targeting novel therapy for peritoneal cancer patients.
• Eindhoven University of TechnologycoreStrategic or Co-development PartnerOriginator of SupraPolix technology through seminal work by Bert Meijer and Rint Sijbesma. Ongoing collaboration on ImaValve project and supramolecular polymer research.
• XeltiscoreStrategic or Co-development PartnerIndustrial partner in ImaValve project developing synthetic heart valve that transforms into living heart valve at implantation site.
• University Hospital ZürichcoreStrategic or Co-development PartnerAcademic partner in ImaValve project contributing expertise in biomaterials science and tissue engineering for cardiovascular applications.
• MediCutminorStrategic or Co-development PartnerPartner in ImaValve project contributing to development of bioresorbable implants for cardiovascular tissue engineering.
• AppletreeminorStrategic or Co-development PartnerPartner in ImaValve project contributing to the development of synthetic heart valve technology.
• University Hospital LeuvencoreStrategic or Co-development PartnerAcademic hospital partner in 4-year international consortium developing bioabsorbable meshes for pelvic organ prolapse and polymeric coils for intracranial aneurysms.
• ColoplastcoreStrategic or Co-development PartnerIndustrial partner in international consortium developing bioabsorbable implants for urologic conditions including pelvic organ prolapse repair meshes.
• LifeTec GroupminorStrategic or Co-development PartnerPartner in consortium developing bioabsorbable implants, contributing expertise in medical device development and testing.
• EurecatminorStrategic or Co-development PartnerResearch center partner in international consortium developing bioabsorbable implants for urologic and embolic conditions.
• Neos SurgeryminorStrategic or Co-development PartnerIndustrial partner in consortium developing polymeric coils for intracranial aneurysms.
• University Hospital AntwerpminorStrategic or Co-development PartnerAcademic hospital partner in international consortium developing bioabsorbable implants.
• Lodz UniversityminorStrategic or Co-development PartnerAcademic partner in consortium contributing research expertise in bioabsorbable polymer materials.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Henkel: Global leader in adhesives, sealants, and functional coatings. Comparable as both a potential large-volume licensee for SupraB technology and a benchmark incumbent whose product portfolios overlap with SupraPolix's go-to-market applications.
• Evonik: German specialty chemicals company active in specialty polymers, adhesives additives, and biomedical materials. Comparable as a broad incumbent with self-healing and functional polymer R&D programs that could compete with or license from SupraPolix.
• H.B. Fuller: Global specialty adhesives and sealants manufacturer. Comparable to SupraPolix as a large-scale customer and potential licensee for self-healing adhesive chemistries in the same end-market SupraPolix targets.
• dsm-firmenich: Global specialty materials and nutrition company with a biomedical materials business (formerly DSM Biomedical). Comparable to SupraPolix as a broad incumbent in specialty polymers and a strategic investor (via DSM Venturing) in the same supramolecular chemistry space.
• Syensqo: Specialty chemicals spin-off of Solvay with strong positions in advanced polymers, composite materials, and biomaterials. Comparable as a broad incumbent whose specialty polymer portfolio overlaps with SupraPolix's coatings, adhesives, and biomedical targets.
• BASF: World's largest chemical company with significant R&D in self-healing polymers, coatings, and biomedical materials. Comparable as a broad incumbent with the resources to out-license or develop competing supramolecular polymer solutions.
• Arkema: French specialty chemicals group with significant adhesives (Bostik), coating solutions, and advanced materials businesses. Comparable as a broad incumbent operating in self-healing/specialty polymer R&D and serving SupraPolix's target industrial applications.

Emerging players

• Hybrid Plastics: Specialty nanomaterials company commercializing POSS (polyhedral oligomeric silsesquioxane) additives that modify polymer properties. Comparable to SupraPolix in selling enabling polymer additives through licensing/supply to industrial customers.
• NEI Corporation: U.S. specialty materials company developing functional coatings, self-healing materials, and battery materials. Comparable to SupraPolix as a small specialist commercializing advanced functional polymer systems to industrial clients.

Direct peers

• Autonomic Materials: U.S.-based specialty materials company focused on self-healing polymer and coating systems. Directly comparable to SupraPolix as a smaller specialist commercializing intrinsic self-healing chemistries for industrial coatings and adhesives.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Suprapolix